Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MSH2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MSH2 negative + MSH6 negative (1)

MSH2 negative + MSH6 negative (1)

›

MSH2 mutation	Gastric Cancer	MSH2 mutation	Gastric Cancer	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2	tremelimumab Sensitive: C2 – Inclusion Criteria tremelimumab Sensitive : C2
MSH2 mutation	Gastric Cancer	MSH2 mutation	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
MSH2 mutation	Pancreatic Ductal Adenocarcinoma	MSH2 mutation	Pancreatic Ductal Adenocarcinoma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MSH2 mutation	Colorectal Cancer	MSH2 mutation	Colorectal Cancer	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3
MSH2 mutation	Urothelial Cancer	MSH2 mutation	Urothelial Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH2 mutation	Rectal Cancer	MSH2 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH2 mutation	Adrenal Cortex Carcinoma	MSH2 mutation	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4